O	0	1	A
O	2	12	randomized
O	13	23	controlled
O	24	29	trial
O	30	37	testing
O	38	39	a
B-intervention	40	50	hyaluronic
I-intervention	51	55	acid
I-intervention	56	62	spacer
I-intervention	63	72	injection
O	73	76	for
B-condition	77	81	skin
I-condition	82	90	toxicity
O	91	100	reduction
O	101	103	of
O	104	117	brachytherapy
O	118	129	accelerated
O	130	137	partial
O	138	144	breast
O	145	156	irradiation
O	157	158	(
O	158	162	APBI
O	162	163	)
O	163	164	:
O	165	166	a
O	167	172	study
O	173	181	protocol
O	181	182	.

O	183	194	Accelerated
O	195	202	partial
O	203	209	breast
O	210	221	irradiation
O	222	223	(
O	223	227	APBI
O	227	228	)
O	229	231	is
O	232	233	a
O	234	243	treatment
O	244	250	option
O	251	254	for
O	255	263	selected
O	264	269	early
O	270	275	stage
O	276	282	breast
O	283	289	cancer
O	290	298	patients
O	298	299	.

O	300	304	Some
O	305	309	APBI
O	310	320	techniques
O	321	325	lead
O	326	328	to
O	329	333	skin
O	334	342	toxicity
O	343	347	with
O	348	351	the
O	352	356	skin
O	357	361	dose
O	362	364	as
O	365	369	main
O	370	374	risk
O	375	381	factor
O	381	382	.

O	383	385	We
O	386	397	hypothesize
O	398	402	that
O	403	404	a
O	405	411	spacer
O	412	420	injected
O	421	428	between
O	429	432	the
O	433	437	skin
O	438	441	and
O	442	448	target
O	449	455	volume
O	456	463	reduces
O	464	467	the
O	468	472	skin
O	473	477	dose
O	478	481	and
O	482	492	subsequent
O	493	501	toxicity
O	502	504	in
O	505	514	permanent
O	515	521	breast
O	522	526	seed
O	527	534	implant
O	535	536	(
O	536	540	PBSI
O	540	541	)
O	542	550	patients
O	550	551	.

O	552	554	In
O	555	559	this
O	560	568	parallel
O	568	569	-
O	569	574	group
O	574	575	,
O	576	582	single
O	582	583	-
O	583	589	center
O	589	590	,
O	591	601	randomized
O	602	612	controlled
O	613	618	trial
O	618	619	,
O	620	623	the
O	624	630	effect
O	631	633	of
O	634	635	a
O	636	648	subcutaneous
O	649	655	spacer
O	656	665	injection
O	666	668	on
O	669	673	skin
O	674	682	toxicity
O	683	688	among
O	689	697	patients
O	698	705	treated
O	706	710	with
O	711	715	PBSI
O	716	718	is
O	719	725	tested
O	725	726	.

O	727	738	Eligibility
O	739	742	for
O	743	756	participation
O	757	759	is
O	760	767	derived
O	768	772	from
O	773	786	international
O	787	797	guidelines
O	798	801	for
O	802	810	suitable
O	811	819	patients
O	820	823	for
O	824	831	partial
O	832	838	breast
O	839	851	radiotherapy
O	851	852	,
O	853	854	e
O	854	855	.
O	855	856	g
O	856	857	.
O	858	863	women
O	864	868	aged
B-age	869	870	≥
I-age	871	873	50
I-age	874	879	years
B-eligibility	880	884	with
I-eligibility	885	886	a
I-eligibility	887	901	histologically
I-eligibility	902	908	proven
I-eligibility	909	912	non
I-eligibility	912	913	-
I-eligibility	913	920	lobular
I-eligibility	921	927	breast
I-eligibility	928	937	carcinoma
I-eligibility	938	941	and
I-eligibility	941	942	/
I-eligibility	942	944	or
I-eligibility	945	951	ductal
I-eligibility	952	961	carcinoma
I-eligibility	962	964	in
I-eligibility	965	969	situ
I-eligibility	970	971	(
I-eligibility	971	975	DCIS
I-eligibility	975	976	)
I-eligibility	976	977	,
I-eligibility	978	983	tumor
I-eligibility	984	988	size
I-eligibility	989	990	≤
I-eligibility	991	992	3
I-eligibility	993	995	cm
I-eligibility	995	996	,
I-eligibility	997	1001	node
I-eligibility	1001	1002	-
I-eligibility	1002	1010	negative
I-eligibility	1010	1011	,
I-eligibility	1012	1015	and
I-eligibility	1016	1020	PBSI
I-eligibility	1021	1032	technically
I-eligibility	1033	1041	feasible
O	1041	1042	.

O	1043	1048	Among
O	1049	1058	exclusion
O	1059	1067	criteria
O	1068	1071	are
O	1072	1083	neoadjuvant
O	1084	1096	chemotherapy
O	1096	1097	,
O	1098	1112	lymphovascular
O	1113	1121	invasion
O	1121	1122	,
O	1123	1126	and
O	1127	1134	allergy
O	1135	1138	for
O	1139	1149	hyaluronic
O	1150	1154	acid
O	1154	1155	.

O	1156	1159	For
O	1160	1163	the
O	1164	1172	patients
O	1173	1182	allocated
O	1183	1185	to
O	1186	1193	receive
O	1194	1200	spacer
O	1200	1201	,
O	1202	1207	after
O	1208	1211	the
O	1212	1216	PBSI
O	1217	1226	procedure
O	1226	1227	,
O	1228	1229	4
O	1229	1230	-
O	1230	1232	10
O	1233	1235	cc
O	1236	1238	of
O	1239	1252	biodegradable
O	1253	1263	hyaluronic
O	1264	1268	acid
O	1269	1270	(
O	1270	1278	Barrigel
O	1278	1279	™
O	1279	1280	,
O	1281	1288	Palette
O	1289	1293	Life
O	1294	1302	Sciences
O	1302	1303	,
O	1304	1309	Santa
O	1310	1317	Barbara
O	1317	1318	,
O	1319	1321	CA
O	1321	1322	,
O	1323	1326	USA
O	1327	1329	or
O	1330	1339	Restylane
O	1340	1344	SubQ
O	1344	1345	®
O	1345	1346	,
O	1347	1355	Galderma
O	1356	1363	Benelux
O	1363	1364	,
O	1365	1370	Breda
O	1370	1371	,
O	1372	1375	the
O	1376	1387	Netherlands
O	1387	1388	)
O	1389	1391	is
O	1392	1400	injected
O	1401	1409	directly
O	1410	1415	under
O	1416	1419	the
O	1420	1424	skin
O	1425	1430	using
O	1431	1441	ultrasound
O	1442	1450	guidance
O	1451	1453	to
O	1454	1460	create
O	1461	1463	an
O	1464	1469	extra
O	1470	1471	0
O	1471	1472	.
O	1472	1473	5
O	1473	1474	-
O	1474	1475	1
O	1476	1478	cm
O	1479	1484	space
O	1485	1492	between
O	1493	1496	the
O	1497	1506	treatment
O	1507	1513	volume
O	1514	1517	and
O	1518	1521	the
O	1522	1526	skin
O	1526	1527	.

O	1528	1531	The
O	1532	1539	primary
O	1540	1547	outcome
O	1548	1550	is
O	1551	1554	the
B-outcome-Measure	1555	1559	rate
I-outcome-Measure	1560	1562	of
I-outcome-Measure	1563	1577	telangiectasia
I-outcome-Measure	1578	1580	at
I-outcome-Measure	1581	1584	two
I-outcome-Measure	1585	1590	years
O	1590	1591	,
O	1592	1599	blindly
O	1600	1608	assessed
O	1609	1614	using
O	1615	1622	Bentzen
O	1622	1623	'
O	1623	1624	s
O	1625	1626	4
O	1626	1627	-
O	1627	1632	point
O	1633	1638	scale
O	1638	1639	.

O	1640	1649	Secondary
O	1650	1658	outcomes
O	1659	1666	include
O	1666	1667	:
B-outcome-Measure	1668	1673	local
I-outcome-Measure	1674	1684	recurrence
O	1684	1685	;
B-outcome-Measure	1686	1693	disease
I-outcome-Measure	1693	1694	-
I-outcome-Measure	1694	1698	free
I-outcome-Measure	1699	1702	and
I-outcome-Measure	1703	1710	overall
I-outcome-Measure	1711	1719	survival
I-outcome-Measure	1720	1725	rates
O	1725	1726	;
B-outcome-Measure	1727	1734	adverse
I-outcome-Measure	1735	1741	events
O	1742	1743	(
O	1743	1747	pain
O	1747	1748	,
O	1749	1756	redness
O	1756	1757	,
O	1758	1762	skin
O	1762	1763	/
O	1763	1775	subcutaneous
O	1776	1786	induration
O	1786	1787	,
O	1788	1797	radiation
O	1798	1808	dermatitis
O	1808	1809	,
O	1810	1822	pigmentation
O	1822	1823	,
O	1824	1832	surgical
O	1833	1837	site
O	1838	1847	infection
O	1847	1848	)
O	1848	1849	;
B-outcome-Measure	1850	1854	skin
I-outcome-Measure	1855	1859	dose
O	1859	1860	;
B-outcome-Measure	1861	1869	cosmetic
I-outcome-Measure	1870	1873	and
I-outcome-Measure	1874	1884	functional
I-outcome-Measure	1885	1892	results
O	1892	1893	;
O	1894	1897	and
B-outcome-Measure	1898	1904	health
I-outcome-Measure	1904	1905	-
I-outcome-Measure	1905	1912	related
I-outcome-Measure	1913	1920	quality
I-outcome-Measure	1921	1923	of
I-outcome-Measure	1924	1928	life
O	1928	1929	.

O	1930	1931	A
O	1932	1938	Fisher
O	1938	1939	'
O	1939	1940	s
O	1941	1946	exact
O	1947	1951	test
O	1952	1956	will
O	1957	1959	be
O	1960	1964	used
O	1965	1967	to
O	1968	1972	test
O	1973	1984	differences
O	1985	1992	between
O	1993	1999	groups
O	2000	2002	on
O	2003	2006	the
O	2007	2014	primary
O	2015	2022	outcome
O	2022	2023	.

O	2024	2032	Previous
O	2033	2040	studies
O	2041	2046	found
O	2047	2049	22
O	2049	2050	.
O	2050	2051	4
O	2051	2052	%
O	2053	2067	telangiectasia
O	2068	2070	at
O	2071	2074	two
O	2075	2080	years
O	2080	2081	.

O	2082	2084	We
O	2085	2091	expect
O	2092	2095	the
O	2096	2099	use
O	2100	2102	of
O	2103	2104	a
O	2105	2111	spacer
O	2112	2117	could
O	2118	2124	reduce
O	2125	2128	the
B-outcome	2129	2139	occurrence
I-outcome	2140	2142	of
I-outcome	2143	2157	telangiectasia
O	2158	2160	to
O	2161	2162	7
O	2162	2163	.
O	2163	2164	7
O	2164	2165	%
O	2165	2166	.

O	2167	2168	A
O	2169	2175	sample
O	2176	2180	size
O	2181	2183	of
B-total-participants	2184	2187	230
O	2188	2196	patients
O	2197	2201	will
O	2202	2207	allow
O	2208	2211	for
O	2212	2213	a
O	2214	2216	10
O	2216	2217	%
O	2218	2222	lost
O	2223	2225	to
O	2226	2232	follow
O	2232	2233	-
O	2233	2235	up
O	2236	2240	rate
O	2240	2241	.

O	2242	2244	In
O	2245	2249	this
O	2250	2255	study
O	2255	2256	,
O	2257	2260	the
O	2261	2267	effect
O	2268	2270	of
O	2271	2272	a
O	2273	2285	subcutaneous
O	2286	2292	spacer
O	2293	2302	injection
O	2303	2305	on
O	2306	2309	the
O	2310	2314	skin
O	2315	2319	dose
O	2319	2320	,
O	2321	2325	late
O	2326	2330	skin
O	2331	2339	toxicity
O	2339	2340	,
O	2341	2344	and
O	2345	2353	cosmetic
O	2354	2361	outcome
O	2362	2364	is
O	2365	2371	tested
O	2372	2374	in
O	2375	2383	patients
O	2384	2391	treated
O	2392	2396	with
O	2397	2401	PBSI
O	2402	2404	in
O	2405	2408	the
O	2409	2416	setting
O	2417	2419	of
O	2420	2426	breast
O	2426	2427	-
O	2427	2437	conserving
O	2438	2445	therapy
O	2445	2446	.

O	2447	2450	Our
O	2451	2458	results
O	2459	2463	will
O	2464	2466	be
O	2467	2475	relevant
O	2476	2479	for
O	2480	2484	most
O	2485	2490	forms
O	2491	2493	of
O	2494	2500	breast
O	2501	2514	brachytherapy
O	2515	2517	as
O	2518	2522	well
O	2523	2525	as
O	2526	2533	robotic
O	2534	2546	radiosurgery
O	2546	2547	,
O	2548	2550	as
O	2551	2555	skin
O	2556	2563	spacers
O	2564	2569	could
O	2570	2577	protect
O	2578	2581	the
O	2582	2586	skin
O	2587	2591	with
O	2592	2597	these
O	2598	2603	other
O	2604	2614	techniques
O	2614	2615	.

O	2616	2627	Netherlands
O	2628	2633	Trial
O	2634	2642	Register
O	2642	2643	,
O	2644	2651	NTR6549
O	2652	2653	.

O	2654	2664	Registered
O	2665	2667	on
O	2668	2670	27
O	2671	2675	June
O	2676	2680	2017
O	2680	2681	.
